Literature DB >> 12471191

Vein of Galen technique for occluding the aneurysmal sac of pulmonary arteriovenous malformations.

Michael G Tal1, Sanjay Saluja, Katharine J Henderson, Robert I White.   

Abstract

In seven of 255 consecutive patients (2.7%) who underwent pulmonary arteriovenous malformation (PAVM) embolization at our center between July 1, 1996, and July 1, 2000, the feeding artery was considered too short for safe occlusion with use of standard stainless-steel coils or detachable balloons. These patients were successfully treated with use of a modified vein of Galen technique similar to the one used for managing intracranial vein of Galen aneurysms. In this article, the authors report their experience with this technique in safely occluding the aneurysmal sacs of PAVMs in patients with short (<2 cm) feeding pulmonary arteries.

Entities:  

Mesh:

Year:  2002        PMID: 12471191     DOI: 10.1016/s1051-0443(07)61975-7

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  4 in total

1.  Complications of embolization.

Authors:  José I Bilbao; Antonio Martínez-Cuesta; Femín Urtasun; Octavio Cosín
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

Review 2.  Pulmonary arteriovenous malformations: what the interventional radiologist needs to know.

Authors:  Andrea Contegiacomo; Annemilia Del Ciello; Rossella Rella; Nico Attempati; Davide Coppolino; Anna Rita Larici; Carmine Di Stasi; Giuseppe Marano; Riccardo Manfredi
Journal:  Radiol Med       Date:  2019-06-17       Impact factor: 3.469

3.  Successful lobectomy for central large pulmonary arteriovenous malformation.

Authors:  Takashi Kanou; Yasushi Shintani; Keigo Osuga; Meinoshin Okumura
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-20

Review 4.  Hereditary haemorrhagic telangiectasia: a cause of preventable morbidity and mortality.

Authors:  A P Brady; M M Murphy; T M O'Connor
Journal:  Ir J Med Sci       Date:  2008-10-16       Impact factor: 1.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.